公开(公告)号：US20220185790A1

公开(公告)日：2022-06-16

申请号：US17593110

申请日：2020-03-12

申请人： Amgen Inc. ,  Cytokinetics, Inc.

发明人： Stephanie AZALI ,  Mary CHAVES ,  Ron C. KELLY ,  Steven M. MENNEN ,  Darren L. REID ,  Osama SULEIMAN ,  Ashraf WILSILY ,  Mark WRIGHT

IPC分类号： C07D401/06

摘要： Provided herein are free base crystalline forms, crystalline salts, solvates, amorphous free base, and cocrystals of Compound A.

公开(公告)号：US20240199550A1

公开(公告)日：2024-06-20

申请号：US18416741

申请日：2024-01-18

申请人： Amgen Inc. ,  Cytokinetics, Inc.

发明人： Henry MORRISON ,  Sheng CUI ,  Kyle QUASDORF ,  Evelyn YANEZ ,  Bin Peter QUAN ,  Ron C. KELLY ,  Sebastien CAILLE ,  Lingyun XIAO ,  David PEARSON ,  Jaclyn RAEBURN ,  Alisa GOLIGHTLY ,  Bradley MORGAN ,  Matthew PETERSON ,  Alex EBERLIN ,  Alexander OBLEZOV

IPC分类号： C07D213/75

CPC分类号： C07D213/75 ,  C07B2200/13

摘要： Provided herein are free base crystalline forms, crystalline salts, and an amorphous salts of omecamtiv mecarbil.

公开(公告)号：US20220257607A1

公开(公告)日：2022-08-18

申请号：US17629824

申请日：2020-04-23

申请人： Amgen Inc.

发明人： Ron C. KELLY ,  Michael T. KENNEDY ,  Stevedat K. LA

IPC分类号： A61K31/553 ,  A61K47/69 ,  A61K47/18 ,  A61K47/02 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02

摘要： Formulations of compounds of Formula I are provided as are doses and dosing regimens useful in methods of treating cancer including hematological malignances such as acute myelogenous leukemia, multiple myeloma, and non-Hodgkin's lymphoma.

公开(公告)号：US20220235045A1

公开(公告)日：2022-07-28

申请号：US17612717

申请日：2020-05-20

申请人： Amgen Inc.

发明人： Mary CHAVES ,  Ron C. KELLY ,  Prashant AGARWAL ,  Stephan D. PARENT ,  Darren Leonard REID ,  Roman SHIMANOVICH

IPC分类号： C07D471/04 ,  A61P35/00

摘要： The present invention provides a crystalline form and stable salts of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1- piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several hydrochloride salt forms, phosphate salt form, mesylate salt form, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.

公开(公告)号：US20240067647A1

公开(公告)日：2024-02-29

申请号：US18382927

申请日：2023-10-23

申请人： AMGEN INC.

发明人： Mary CHAVES ,  Patricia LOPEZ ,  Prashant AGARWAL ,  Albert AMEGADZIE ,  Stephanie AZALI ,  Roman SHIMANOVICH ,  Ron C. KELLY ,  Darren Leonard REID

IPC分类号： C07D471/04

CPC分类号： C07D471/04 ,  C07B2200/13

摘要： The present disclosure provides crystalline and amorphous forms of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several anhydrous, hydrate and solvate forms, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.

公开(公告)号：US20220106313A1

公开(公告)日：2022-04-07

申请号：US17553598

申请日：2021-12-16

申请人： AMGEN INC.

发明人： Mary CHAVES ,  Patricia LOPEZ ,  Prashant AGARWAL ,  Albert AMEGADZIE ,  Stephanie AZALI ,  Roman SHIMANOVICH ,  Ron C. KELLY ,  Darren Leonard REID

IPC分类号： C07D471/04

摘要： The present disclosure provides crystalline and amorphous forms of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several anhydrous, hydrate and solvate forms, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.

公开(公告)号：US20200369662A1

公开(公告)日：2020-11-26

申请号：US16878824

申请日：2020-05-20

申请人： AMGEN INC.

发明人： Mary CHAVES ,  Patricia LOPEZ ,  Prashant AGARWAL ,  Albert AMEGADZIE ,  Stephanie AZALI ,  Roman SHIMANOVICH ,  Ron C. KELLY ,  Darren Leonard REID

IPC分类号： C07D471/04

摘要： The present disclosure provides crystalline and amorphous forms of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several anhydrous, hydrate and solvate forms, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.